Surgical Science Sweden Ab · OMXSTO:SUS

Surgical Science Sweden Ab — Surgical Science — Q1 2026 Earnings Presentation

10 slides from Surgical Science Sweden Ab's earnings presentation, May 2026

  1. Slide 1: Presentation of Interim Report Q1

    Presentation of Interim Report Q1 ©2025 Surgical Science. | All rights reserved.

  2. Slide 2: CEO comments – Q1 2026

    CEO comments – Q1 2026 Revenue Adjusted EBIT  Solid start to the year SEK 235.5m SEK 28.3m ▫ Revenue growth of 4% in local currencies. -6% reported | +4% fx-adj. 12% margin | 16% ▫ Adjusted EBIT at 12%, slightly below financial targets fx-adj.  Educational Products 14% growth in local currencies ▫

  3. Slide 3: Q1: A solid start to the year

    Q1: A solid start to the year SEKm Q1 250  Net sales down 6% to SEKm 235.5 250.7. In local currencies up 4%. 200 47% 52%  Educational Products up 6%, 14% excl. FX. 45% 50% 51% 45% Regions: EMEA 82%, APAC 25%, Americas - 48% 24%. 47% 150  Industry down 17%, 7% excl. FX. License revenues 58% d

  4. Slide 4: Revenue streams

    Revenue streams SEKm 8% 2% 8% 250 4%  License revʼs: 29% 33) of total revenues. 4% 3% 6% Intuitive sales down due to going back to old 4% 30% 11% 25% agreement. Revenues from several other 200 5% 28% 33% 34% customers. 33% 29% 32% 8% 9%  Simulator sales down 2%. 150 28% 34% 10% 9% 9% 10% 9%  Dev

  5. Slide 5: Costs and EBIT margin Q1 2026

    Costs and EBIT margin Q1 2026  Gross margin 66% 69. Lower license revenues, FX and lower proportion of direct sales had a negative Costs/margin as a percentage of sales effect. Price increases had a positive effect.  Sales: 21% 20) of sales. SEKm 2.4 in tariffs on Cost of goods sold 34% 31 si

  6. Slide 6: Organization

    Organization No of employees at end of period: 317 (336) Men 228 233 Women 89 103 Israel 155 146 Sweden 71 70 USA 40 63 UK 29 39 Other 22 18 * Offices / Development sites * Other: Primarily Germany and China. 5

  7. Slide 7: Adjusted EBIT

    Adjusted EBIT* SEKm 50% 250 Q1 40% 200  Adjusted EBIT SEKm 28.3 30.1. Adjusted for acquisition 30% 150 and restructuring costs EBIT in the comparison period 100 20% amounted to SEKm 56.6. 10%  FX-adjusted adjusted EBIT 50 SEKm 42.0 or 16%. 0 0% Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 2024 2025 2026 -50 -10%

  8. Slide 8: Finance net and taxes

    Finance net and taxes  Finance net for the quarter SEKm 1.2 22.3. Interest on bank balances, revaluation of internal loans and IFRS 16 effect.  Tax expense for the quarter SEKm 3.0 13.0.  Net result for the quarter SEKm 18.6 33.2. 7

  9. Slide 9: Cash flow

    Cash flow SEKm 800 18%  Cash flow from operating activities SEKm 700 16% 65.3 5.0. Change in working capital 14% SEKm 35.6 34.1. Inventory unchanged, 600 A/R and current receivables decreased. 12% 500 10%  Cash flow from investing activities SEKm 400 18.0 95.6) mainly investments in 8% 30

  10. Slide 10: Thank you

    Thank you Find out more at: www.surgicalscience.com ©2025 Surgical Science. | All rights reserved.

Surgical Science — Q1 2026 Earnings Presentation on 6ix